Posters and Oral presentations
Society for Immunotherapy of Cancer (SITC) Annual Meeting, 10th November 2022
Repeat dosing of oncolytic adenovirus ONCOS-102 is associated with enhanced and persistent immune responses and improved systemic activity in anti-PD-1 resistant melanoma
American Association for Cancer Research (AACR) Annual Meeting, 11th April 2022
Modulation of immune gene expression by intra tumoral oncolytic adenovirus ONCOS 102 is associated with clinical response in anti PD 1 refractory/resistant melanoma
13 November 2021 at the SITC congress
Consistent pattern of immune activation induced by oncolytic adenovirus ONCOS-102 across diverse types of solid tumors
13 November 2021 at the SITC congress
A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 24-month survival data
European Society for Medical Oncology (ESMO) congress, 16-21 September 2021
"A pilot study of Engineered Adenovirus ONCOS-102 in combination with pembrolizumab (pembro) in checkpoint inhibitor refractory advanced or unresectable melanoma"
Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting, 9-14 November 2020
"A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12-month analysis of biomarkers and clinical outcomes"
American Society of Clinical Oncology (ASCO) Annual Meeting, 29 May - 2 June 2020.
"Phase 1/2 Study to Evaluate Systemic Durvalumab + Intraperitoneal ONCOS-102 in Patients with Peritoneal Disease who have Epithelial Ovarian or Metastatic Colorectal Cancer: Interim Phase 1 Clinical and Translational Results"
American Association for Cancer Research (AACR) Virtual Annual Meeting, 22-24 June 2020
"Next generation ONCOS oncolytic adenovirus with novel anti-cancer double-transgenes shows
synergistic anti-cancer effect in a melanoma mouse model"
ASGCT, virtual conference Next-gen virus poster 12-15 May 2020
“Next generation ONCOS double transgene oncolytic adenovirus exhibits enhanced anti-cancer effect in pre-clinical melanoma model”
ASGCT, virtual conference Next-gen virus poster 12-15 May 2020
“Oncolytic Adenovirus Ad5/3-D24-GM-CSF Infects, Replicates and Lyses Ovarian Cancer Cells Through Desmoglein-2 Cell Entry Receptor”
13th International Adenovirus Meeting, September 2018 – POSTER
Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 in peritoneal mesothelioma mouse model
21st Annual Meeting ASGCT, May 2018 – POSTER
The combinatory treatment of the oncolytic adenovirus ONCOS-102 with anti PD-1 (KEYTRUDA®) show synergistic anti-tumor effect in humanized A2058 melanoma huNOG mouse model
ESMO 2017 Congress, September 2017 – POSTER
ONCOS-102 and Pemetrexed/cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma
SITC 30th Annual Meeting, Nov 2015 – POSTER
Local immunotherapy with ONCOS-102 shapes harmful tumor associated CD68+ macrophages to become beneficial cells that correlate with increased overall survival
ASCO Annual Meeting, May 2015 – POSTER
An evaluation of local and systemic immune markers following intratumoral administration of a chimeric adenovirus Ad5/3-D24-GMCSF in refractory cancer patients with solid tumors
EORTC-NCI-AACR, Nov 2014 – POSTER
Tumor-infiltrating lymphocytes (TILs) following intratumoral administration of ONCOS-102 are associated with prolonged overall survival in last line solid tumor patients
SITC 29th Annual Meeting, Nov 2014 – POSTER
Gene expression analysis of tumors demonstrates an induction of Th1 type immune response following intratumoral administration of ONCOS-102 in refractory solid tumor patients
CRI Annual International Cancer Immunotherapy Symposium, Oct 2014 – POSTER
Intratumoral ONCOS-102 Shapes the Tumor Microenvironment in Last-Line Refractory Solid Tumor Patients
CIMT Annual Meeting, May 2014 – POSTER & ORAL PRESENTATION
Characterization of tumor-infiltrating lymphocytes following intratumoral administration of ONCOS-102 for refractory solid tumor cancer patients
CIMT Annual Meeting, May 2014 – POSTER & ORAL PRESENTATION
Induction of anti-tumor CD8+ T cells and prominent infiltration of lymphocytes with a Th1 polarizing signature to pleural mesothelioma tumor after intratumoral injection of ONCOS-102
CIMT Annual Meeting, May 2014 – POSTER
Repeated intratumoral administration of ONCOS-102 leads to robust cellular and transcriptional immune activation at tumor site in an ovarian cancer patient